BP-1223

N/A

Report date: 2026/03/19 17:12:17

Base Information

Drug NameBP-1223
Drug Alias NameBP-1223BP1223
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionAnti-Ectonucleoside triphosphate diphosphohydrolase 1Anti-CD3
TargetsEctonucleoside triphosphate diphosphohydrolase 1T cell surface glycoprotein CD3
Therapy Area/IndicationsHematologic NeoplasmsMultiple MyelomaLeukemia, Myeloid, Acute +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesBrightpath Biotherapeutics Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBrightpath Biotherapeutics Co Ltd
Inactive CompaniesN/A
Active IndicationsHematologic NeoplasmsMultiple MyelomaLeukemia, Myeloid, Acute +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A